Gene therapies have been disrupting the way to address fatal diseases, specifically for children. In fact, they have paved the way for various innovative curative therapies. However, these new therapies require a very different approach compared to what has typically existed in terms of drug development, drug production and commercialization, and the delivery to patients. This is especially true in light of the elevated costs that are currently passed on to patients. During this session, we will discuss what is behind such costs and how we can make gene therapies more affordable to patients.
Pr Bruce Levine – Professor in Cancer Gene Therapy at U-penn, President elected at International Society of Cell & Gene therapy
Pr Olivier Blin – Elected member of innovative medicines for EU
Patricia Zilliox - CEO at Eyevensis
Kristin Feerst - Integrated Solutions at Pall Biosciences
Moderator : Michael Salgaller - Supervisory Invention Development at National Institutes of Health / National Cancer Institute.
Mandatory Registration & Photo ID : https://www.eventbrite.com/e/bio-2019-gene-therapy-how-to-make-disruptive-therapies-affordable-for-patients-conference-by-tickets-61426248563
Session ID: 565534